Loss of blast heterogeneity in myelodysplastic syndrome and other chronic myeloid neoplasms.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 25125617.
- Also identified by DOI 10.1309/AJCP73QSLLYDEGXK.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Flow cytometry immunophenotyping has been suggested as an adjunctive technique in the evaluation of myeloid malignancies, especially in the myelodysplastic syndromes. However, its use has been limited due to complexity and cost restraints. The goal of this study is to attempt a simpler approach to flow cytometry immunophenotyping in myeloid neoplasms. We analyzed bone marrow specimens of 45 selected patients and an additional 99 consecutive random patients using a limited antibody panel. Normal CD34-positive blasts show a characteristic pattern of CD13/HLA-DR expression, with three readily identifiable subpopulations. In contrast, myeloid neoplasms frequently show loss of this heterogeneity. Analysis of a limited antibody panel with a focus on CD13/HLA-DR expression provides relatively high specificity and sensitivity for the detection of myeloid neoplasms.
Medical subject headings
- Bone Marrow
- Hematologic Neoplasms
- Myelodysplastic Syndromes
- Myeloproliferative Disorders